Advertisement

Topics

Effectiveness of heliotherapy for psoriasis clearance in low and mid-latitudinal regions: A theoretical approach.

Summary of "Effectiveness of heliotherapy for psoriasis clearance in low and mid-latitudinal regions: A theoretical approach."

The action spectrum for psoriasis clearance is reconstructed taking into account the results obtained in the early 1980s. The antipsoriatic action spectrum is used for weighting the medical cabinet UV spectra, and the solar spectra measured in San Diego (USA) and Belsk (Poland). The mean cumulative antipsoriatic effective dose of 450mJcm(-2), due to TL-01 (UVB narrowband) tubes, is taken by a patient with skin phototype II during routine 20 phototherapy sessions carried out in a phototherapy cabinet in the Medical University of Łódz. Thus, the daily mean dose of value 22.5mJcm(-2) is proposed as the threshold for daily solar dose for numbers of out-door exposures to clear psoriasis. We assume that the heliotherapy will last a whole month with every day 2h exposition to the direct sunlight around local noon. The heliotherapy will be successful if weather conditions permit at least 20days with the daily exposure over the threshold. The minimum cumulative ambient erythemal dose, necessary for psoriasis clearance, is estimated as 144 standard erythema dose (SED) for the whole heliotherapy period. We find that heliotherapy could be effectively used in March through October (San Diego) and in June through August (Belsk). Thus, the heliotherapy against psoriasis is possible not only at southern resorts but even at the mid-latitude sites.

Affiliation

Institute of Geophysics, Polish Academy of Sciences, Warsaw, Poland.

Journal Details

This article was published in the following journal.

Name: Journal of photochemistry and photobiology. B, Biology
ISSN: 1873-2682
Pages: 35-41

Links

DeepDyve research library

PubMed Articles [19533 Associated PubMed Articles listed on BioPortfolio]

Ultraviolet B radiation therapy for psoriasis: Pursuing the optimal regime.

Psoriasis is a chronic and common disease mediated by resident memory T cells that negatively affects a broad range of people worldwide. One of the oldest and most commonly used treatments is photothe...

Reaching complete or near complete resolution of psoriasis: benefit and risk considerations.

The incremental benefits of obtaining higher levels of skin clearance for patients with psoriasis have been established across several patient reported outcomes (PROs). Patients who obtain clear or al...

Update in the management of pediatric psoriasis.

Psoriasis is a multifactorial, chronic, inflammatory skin disease that may represent a therapeutic challenge in children. This review aims to provide a framework for the management of pediatric psoria...

Efficacy and Survival of Systemic Psoriasis Treatments: An Analysis of the Swiss Registry SDNTT.

The Swiss psoriasis registry SDNTT (Swiss Dermatology Network for Targeted Therapies) records the long-term safety and effectiveness of systemic treatment regimens for psoriasis.

Clearance Gap: Does It Really Matter for the Evaluation of Vascular Access Function?

Vascular access (VA) stenosis increases the risk of VA obstruction due to the gradual progress of intimal thickening. Therefore, we should try to detect VA stenosis early. However, we do not have a cu...

Clinical Trials [4073 Associated Clinical Trials listed on BioPortfolio]

Primary UVB-311nm and Adalimumab in Psoriasis Patients

Adalimumab, a fully human anti-tumor necrosis factor (TNF) monoclonal antibody has been approved for the treatment of moderate to severe psoriasis. However, in a portion of cases adalimum...

Narrow-Band UVB-Therapy in Psoriasis

Study on two different irradiation schemes in UVB phototherapy for psoriasis. Previous studies demonstrated a similar clinical effect in erythematogenic and suberythematogenic irradiation,...

UVB-311nm After Initial Slow Response to Adalimumab in Psoriasis

Adalimumab, a fully human anti-tumor necrosis factor (TNF) monoclonal antibody has been approved for the treatment of moderate to severe psoriasis. However, in a portion of cases adalimum...

Canadian Humira Post Marketing Observational Epidemiological Study: Assessing Effectiveness in Psoriasis

The current study will compare the real - life effectiveness of adalimumab to topical and traditional systemic agents in the management of psoriasis and its impact on the patient's quality...

The Corrona Psoriasis Registry

The primary objective of the Corrona Psoriasis Registry is to study the comparative safety of approved psoriasis therapies in a national cohort of psoriasis subjects treated by dermatologi...

Medical and Biotech [MESH] Definitions

Theoretical representations that simulate the behavior or activity of systems, processes, or phenomena. They include the use of mathematical equations, computers, and other electronic equipment.

The treatment of disease by exposing the body to SUNLIGHT, a therapeutic use of SUNBATHING.

A common genetically determined, chronic, inflammatory skin disease characterized by rounded erythematous, dry, scaling patches. The lesions have a predilection for nails, scalp, genitalia, extensor surfaces, and the lumbosacral region. Accelerated epidermopoiesis is considered to be the fundamental pathologic feature in psoriasis.

A non-specific host defense mechanism that removes MUCUS and other material from the LUNGS by ciliary and secretory activity of the tracheobronchial submucosal glands. It is measured in vivo as mucus transfer, ciliary beat frequency, and clearance of radioactive tracers.

Any situation where an animal or human is trained to respond differentially to two stimuli (e.g., approach and avoidance) under reward and punishment conditions and subsequently trained under reversed reward values (i.e., the approach which was previously rewarded is punished and vice versa).

Quick Search
Advertisement
 


DeepDyve research library

Relevant Topic

Alzumab (Itolizumab)
Biocon Launches ALZUMAb™ - a ‘First in Class’ Novel Biologic Treatment for Psoriasis Patients in India • ALZUMAb™-World's first novel anti-CD6 antibody developed by Biocon to address a large unmet need for th...


Searches Linking to this Article